Alphabet Inc.
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 8, 2026), Alphabet Inc. reported 26 stock positions worth $4.0 billion. Its top holding was Cme (CME) at 25.6% of the portfolio, followed by Planet Labs PBC (PL, 24.5%) and Ast Spacemobile (ASTS, 18.5%). Compared with Q4 2025, it opened 3 new positions, sold out of 6, added to 1 and reduced 3. The biggest buy was a new position in Cme (CME) and the biggest sale an exit from Dexcom (DXCM).
- Most Recent 13F
- Q2 2026
- Location
- Mountain View, CA
- CIK
- 0001652044
- Portfolio Value
- $4.0B (Q1 2026)
- SEC Filing
- 0001652044-26-000051 ↗ filed May 8, 2026
Holdings Value
Holdings 26 stocks · $4.0B
| CME Cme Group Inc. | 25.63% | 3,484,020 | $1.0B | New |
| PL Planet Labs PBC | 24.53% | 35,248,893 | $985.2M | Add +10.3% |
| ASTS Ast Spacemobile Inc. | 18.46% | 8,943,486 | $741.1M | No change |
| RVMD Revolution Medicines Inc. | 7.97% | 3,292,525 | $320.2M | Reduce -1.6% |
| ARM Arm Holdings PLC-ADR | 7.39% | 1,960,784 | $296.6M | No change |
| FRSH Freshworks Inc. Class A | 3.24% | 16,206,643 | $130.1M | No change |
| PATH Uipath Inc. Class A | 1.94% | 7,034,337 | $78.1M | No change |
| TEM Tempus AI Inc. Class A | 1.75% | 1,551,102 | $70.1M | No change |
| PAYP Paypay Corp. | 1.66% | 3,125,000 | $66.7M | New |
| GTLB Gitlab Inc. Class A | 1.47% | 2,724,712 | $59.0M | No change |
| PRME Prime Medicine Inc. | 1.44% | 16,562,498 | $57.6M | No change |
| LIFE Ethos Technologies Inc. Class-A | 1.05% | 3,770,156 | $42.1M | New |
| MAZE Maze Therapeutics Inc. | 1.03% | 1,388,583 | $41.4M | No change |
| BBOT Bridgebio Oncology Therapeut | 0.63% | 2,823,126 | $25.3M | No change |
| RLAY Relay Therapeutics Inc. | 0.39% | 1,564,173 | $15.6M | Reduce -0.3% |
| GLUE Monte Rosa Therapeutics Inc. | 0.28% | 684,275 | $11.3M | Reduce -8.1% |
| VERA Vera Therapeutics Inc. | 0.24% | 241,264 | $9.7M | No change |
| SANA Sana Biotechnology Inc. | 0.20% | 2,812,500 | $8.1M | No change |
| BEAM Beam Therapeutics Inc. | 0.19% | 321,604 | $7.7M | No change |
| LYEL Lyell Immunopharma Inc. | 0.15% | 293,256 | $5.9M | No change |
| OSCR Oscar Health Inc. Class A | 0.14% | 481,988 | $5.5M | No change |
| FIG Figma Inc. Class A | 0.11% | 215,582 | $4.6M | No change |
| SPRO Spero Therapeutics Inc. | 0.05% | 889,979 | $2.1M | No change |
| HYPR Hyperfine Inc. | 0.02% | 898,720 | $971K | No change |
| AUTL Autolus Therapeutics PLC | 0.02% | 698,262 | $964K | No change |
| TNYA Tenaya Therapeutics Inc. | 0.02% | 915,705 | $632K | No change |
Portfolio Sells Q4 2025 → Q1 2026
| DXCM Dexcom Inc. | Sold out | 0.00% | −2.67 |
| RVMD Revolution Medicines Inc. | Reduce -1.6% | 7.97% | −2.35 |
| GLUE Monte Rosa Therapeutics Inc. | Reduce -8.1% | 0.28% | −0.17 |
| RLAY Relay Therapeutics Inc. | Reduce -0.3% | 0.39% | −0.13 |
| WGS Genedx Holdings Corp. | Sold out | 0.00% | −0.11 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −0.09 |
| QUINCE THERAPEUTICS INC | Sold out | 0.00% | −0.02 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.01 |
| RGEN Repligen Corp. | Sold out | 0.00% | −0.00 |
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 28 | $99.1B | SPCX, PL, ASTS, CME, ARM |
| Q1 2026 | 26 | $4.0B | CME, PL, ASTS, RVMD, ARM |
| Q4 2025 | 29 | $2.6B | ASTS, PL, RVMD, ARM, FRSH |
| Q3 2025 | 37 | $2.4B | ASTS, PL, ARM, MTSR, RVMD |
| Q2 2025 | 36 | $2.1B | ASTS, ARM, FRSH, PL, RVMD |
| Q1 2025 | 40 | $1.6B | FRSH, ARM, ASTS, RVMD, MTSR |
| Q4 2024 | 40 | $1.7B | GTLB, FRSH, ARM, RVMD, CRWD |
| Q3 2024 | 42 | $1.8B | GTLB, ARM, RVMD, FRSH, CRWD |
| Q2 2024 | 42 | $2.0B | GTLB, ARM, RVMD, CRWD, FRSH |
| Q1 2024 | 43 | $2.5B | GTLB, CRWD, DXCM, ARM, FRSH |